X
Snippet view
Table view
10 Results - per page
| Name |
Description |
Preferred ID |
Type |
ID |
Score | ||
|---|---|---|---|---|---|---|---|
| Minocycline | A tetracycline analog, having a 7-dimethylamino and lacking the 5 methyl and hydroxyl groups, which is effective against tetracycline-resistant staphylococcus infections. (PubChem) Pharmacology: Minocycline, the most lipid soluble and most active tetracycline antibiotic, is, like doxycycline, a long-acting tetracycline. Minocycline's effects are related to the inhibition of protein synthesis. Although minocycline's broader spectrum of activity, compared to other members of the group, includes activity against Neisseria meningitidis, its use as a prophylaxis is no longer recomended because of side effects (dizziness and vertigo). Current research is examining the possible neuroprotective effects of minocycline against progression of Huntington's Disease, an inherited neurodegenerative disorder. The neuroprotective action of minocycline may include its inhibitory effect on 5-lipoxygenase, an inflammatory enzyme associated with brain aging. Mechanism of action: Minocycline passes directly through the lipid bilayer or passively diffuses through porin channels in the bacterial membrane. Tetracyclines like minocycline bind to the 30S ribosomal subunit, preventing the binding of tRNA to the mRNA-ribosome complex and interfering with protein synthesis. Drug type: Approved. Investigational. Small Molecule. Drug category: Anti-Bacterial Agents. Tetracyclines | CHEBI:50694 | term | ILX:0106995 | 24040.645 | Molecular entity, Material entity, Independent continuant, Continuant | minocycline, Alti-Minocycline, Apo-Minocycline, Arestin, Dynacin, Gen-Minocycline, Klinomycin, Minociclina (INN-Spanish), Minocin, Minocyclin, Minocycline HCl, Minocyclinum (INN-Latin), Minocyn, Minomycin, Novo-Minocycline, Solodyn |
| Minocycline | A TETRACYCLINE analog, having a 7-dimethylamino and lacking the 5 methyl and hydroxyl groups, which is effective against tetracycline-resistant STAPHYLOCOCCUS infections. | MESH:M0013912 | term | ILX:0737458 | 23276.479 | ||
| Apo-Minocycline | MESH:M0474858 | term | ILX:0498866 | 326.62796 | |||
| 9-(N,N-dimethylglycylamido)minocycline | MESH:M0226440 | term | ILX:0472465 | 228.65529 | |||
| Minocycline, (4R-(4 alpha,4a beta,5a beta,12a beta))-Isomer | MESH:M0330038 | term | ILX:0413348 | 161.24872 | |||
| Treatment | Treatment administered (e.g. DMSO, saline, minocycline, etc) | ILX.CDE:0100181 | cde | CDE:0100181 | 13.592404 | ||
| Cytochrome c | A small heme protein found loosely associated with the inner membrane of the mitochondrion. | ILX:0102765 | term | ILX:0102765 | 11.838674 | Protein, Molecular entity, Material entity, Independent continuant, Continuant | |
| Drug | Any substance which when absorbed into a living organism may modify one or more of its functions. The term is generally accepted for a substance taken for a therapeutic purpose, but is also commonly used for abused substances. | CHEBI:23888 | term | ILX:0103576 | 7.6843243 | Molecule role, Role, Realizable entity, Specifically dependent continuant, Dependent continuant, Continuant | |
| Doxycycline | A synthetic tetracycline derivative with similar antimicrobial activity. Animal studies suggest that it may cause less tooth staining than other tetracyclines. It is used in some areas for the treatment of chloroquine-resistant falciparum malaria (malaria, falciparum). (PubChem) Pharmacology: Doxycycline, a long-acting tetracycline derived from oxytetracycline, is used to inhibit bacterial protein synthesis and treat non-gonococcal urethritis and cervicitis, exacerbations of bronchitis in patients with COPD, and adult periodontitis. Mechanism of action: Doxycycline, like minocycline, is lipophilic and can pass through the lipid bilayer of bacteria. Doxycycline reversibly binds to the 30 S ribosomal subunits and possibly the 50S ribosomal subunit(s), blocking the binding of aminoacyl tRNA to the mRNA and inhibiting bacterial protein synthesis. Drug type: Approved. Investigational. Small Molecule. Drug category: Anti-Bacterial Agents. Antimalarials. Tetracyclines | CHEBI:50845 | term | ILX:0103546 | 2.529339 | Molecular entity, Material entity, Independent continuant, Continuant | Doxcycline anhydrous, Doxycycline Hyclate, Doxycycline Monohydrate, Doxytetracycline, Alti-Doxycycline, Apo-Doxy, Atridox, Doryx, Doxy 100, Doxy-Caps, Doxy-Lemmon, Doxychel, Doxychel Hyclate, Doxycin, Doxylin, Doxytec, Jenacyclin, Monodox, Novo-Doxylin, Nu-Doxycycline, Oracea, Periostat, Supracyclin, Vibra-Tabs |
| Tigecycline | Tigecycline is a glycylcycline antibiotic developed and marketed by Wyeth under the brand name Tygacil. It was given a U.S. Food and Drug Administration (FDA) fast-track approval and was approved on June 17, 2005. It was developed in response to the growing prevalence of antibiotic resistance in bacteria such as Staphylococcus aureus. Pharmacology: Tigecycline is the first clinically-available drug in a new class of antibiotics called the glycylcyclines. Glycylcyclines are a new class of antibiotics derived from tetracycline. These tetracycline analogues are specifically designed to overcome two common mechanisms of tetracycline resistance, namely resistance mediated by acquired efflux pumps and/or ribosomal protection. Glycylcycline antibiotics have a similar mechanism of action as tetracycline antibiotics. Both classes of antibiotics bind to the 30S ribosomal subunit to prevent the amino-acyl tRNA from binding to the A site of the ribosome. However, the glycylcyclines appear to bind more effectively than the tetracyclines. Mechanism of action: Tigecycline, a glycylcycline, inhibits protein translation in bacteria by binding to the 30S ribosomal subunit and blocking entry of amino-acyl tRNA molecules into the A site of the ribosome. This prevents incorporation of amino acid residues into elongating peptide chains. Tigecycline carries a glycylamido moiety attached to the 9-position of minocycline. The substitution pattern is not present in any naturally occurring or semisynthetic tetracycline and imparts certain microbiologic properties to tigecycline. Tigecycline is not affected by the two major tetracycline resistance mechanisms, ribosomal protection and efflux. Accordingly, tigecycline has demonstrated in vitro and in vivo activity against a broad spectrum of bacterial pathogens. There has been no cross resistance observed between tigecycline and other antibiotics. Tigecycline is not affected by resistance mechanisms such as beta-lactamases (including extended spectrum beta-lactamases), target site modifications, macrolide efflux pumps or enzyme target changes (e.g. gyrase/topoisomerase). In vitro studies have not demonstrated antagonism between tigecycline and other commonly used antibacterial drugs. In general, tigecycline is considered bacteriostatic. Drug type: Small Molecule. Drug category: Anti-Bacterial Agents. Antibacterial Agents. Tetracyclines | ILX:0111741 | term | ILX:0111741 | 1.0692464 | Molecular entity, Material entity, Independent continuant, Continuant | GAR-936, GAR-936,Tigecycline, WAY-GAR-936 |
Preparing word cloud
About
The SciCrunch Infrastructure was developed as a cooperative data platform to be used by diverse communities in making data more FAIR.
Contact Us
FAIR Data Informatics Lab
University of California, San Diego
9500 Gilman Drive, Mail Code 0608
La Jolla, CA 92093-0608
United States
info 
scicrunch.org
scicrunch.orgX